Session 204
Executing the Biggest, Most Complex Oncology Alliance in Recent History–Learnings from the First Eighteen Months Together

In March 2019 Daiichi Sankyo and AstraZeneca announced a $6.9Bn global alliance to co-develop and co-commercialize DS-8201. Eighteen months, a US launch, a global pandemic, three breakthrough designations, and several additional filings later Kenji Shigeta and Jon Bell, the lead alliance managers reflect on the challenges of implementing the alliance.

During their presentation, Kenji and Jon will:


Jonathan Bell
Director, Alliance and Integration Management

Jon Bell joined AstraZeneca's Business Development Operations group based in Cambridge, UK in 2015. He has over 25 years' experience in the Pharmaceutical Industry. This is his second spell at AstraZeneca having previously worked in the UK affiliate's New Product Planning team from 2003 to 2010.

Recently Jon has worked on a number of major transactions at AstraZeneca including the sale of AstraZeneca's small molecule antibiotics business to Pfizer in 2016 and various divestments before moving to the Alliance Management team in 2017 to help manage the LYNPARZA alliance with Merck, which he still supports. In 2019, Jon took the Lead Alliance Manager role on the global alliance with Daiichi Sankyo.

Kenji Shigeta
Vice President, Business Strategy, Global Brand Strategy Unit
Daiichi Sankyo

Kenji Shigeta joined Daiichi Sankyo's Global Brand Strategy Unit – DS-8201 Business Strategy group in Tokyo, Japan in 2019. He has over 25 years' experience in the pharmaceutical industry. Before taking the current position, he led New Product Planning (NPP) team in Global Oncology Marketing.

Kenji worked on several ADC (Antibody Drug Conjugate) projects such as DS-8201 (ENHERTU), U3-1402 (HER3-ADC), DS-1062 (TROP2-ADC) in NPP, which are major oncology assets in Daiichi Sankyo. In 2019, a new group was established to expand DS-8201 global business with AstraZeneca. Kenji took the Lead Alliance Manager role on the global alliance.